Leptomeningeal Disease in Melanoma: An Update on the Developments in Pathophysiology and Clinical Care

Authors

Inna Smalley
Adrienne Boire
Priscilla Brastianos
Harriet M Kluger
Eva Hernando-Monge
Peter A Forsyth
Kamran A Ahmed
Keiran S M Smalley
Sherise Ferguson
Michael A Davies
Isabella C Glitza Oliva

Language

English

Publication Date

1-1-2024

Journal

Pigment Cell & Melanoma Research

DOI

10.1111/pcmr.13116

PMID

37622466

PMCID

PMC12292448

PubMedCentral® Posted Date

7-27-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Leptomeningeal disease (LMD) remains a major challenge in the clinical management of metastatic melanoma patients. Outcomes for patient remain poor, and patients with LMD continue to be excluded from almost all clinical trials. However, recent trials have demonstrated the feasibility of conducting prospective clinical trials in these patients. Further, new insights into the pathophysiology of LMD are identifying rational new therapeutic strategies. Here we present recent advances in the understanding of, and treatment options for, LMD from metastatic melanoma. We also annotate key areas of future focus to accelerate progress for this challenging but emerging field.

Keywords

Humans, Melanoma, Prospective Studies, Radiosurgery

Published Open-Access

yes

Recommended Citation

Smalley, Inna; Boire, Adrienne; Brastianos, Priscilla; et al., "Leptomeningeal Disease in Melanoma: An Update on the Developments in Pathophysiology and Clinical Care" (2024). Faculty, Staff and Student Publications. 5509.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5509